Jiangbo Pharmaceuticals, Inc.(fka JGBO)

[996]

Transcript of Conference Call:

Genesis Pharmaceuticals Enterprises, Inc. (GNPH.OB)

F1Q09 (Qtr End 09/30/08) Earnings Call Transcript

November 17, 2008, 10:00 am ET

Executives

Crocker Coulson - President, CCG

Xu Haibo - COO

Elsa Sung - CFO

Analysts

Louis Mark

Lu Jeans

Jen Hue

Angel Lew

Peter Styris


Presentation

Operator

Good day, ladies and gentlemen, and welcome to the Genesis Pharmaceuticals’ Earnings Conference Call. My name is Jessica, and I will be your coordinator for today. At this time, all participants are in listen-only mode. We will be facilitating a question-and-answer session towards the end of this conference. (Operator Instructions). As a reminder, this conference is being recorded for replay purposes.

I would now like to turn the presentation over to your host for today’s call, Mr. Crocker Coulson, President of CCG. Please proceed, sir.

Crocker Coulson

Hi. Thank you very much, operator. Good morning everybody, and welcome to Genesis Pharmaceuticals’ first quarter of fiscal 2009 earnings conference call. I am Crocker Coulson, and with us today on the call are Mr. Xu, Genesis Pharmaceuticals’ Chief Operating Officer, and also the company’s Chief Financial Officer, Ms. Elsa Sung.

Before I turn this call over to company’s management, I’d like to remind our listeners, in this call management’s prepared remarks contain forward-looking statements which are subject to risks and uncertainties, and management may make additional forward-looking statements in response to your questions.

Therefore, the company claims the protection for forward-looking statements that’s contained in the Private Securities Litigation Reform Act of 1995. Actual results may differ from those discussed today and, therefore, we’d like to refer you to a more detailed discussion of these risks and uncertainties in the company’s filings with the SEC.

In addition, any projection as the company’s future performance represent management’s estimates as of today, November 17th, 2008, and Genesis Pharmaceuticals assumes no obligation to update these projections in the future as market conditions change.

It’s now my pleasure to turn the call over to Mr. Xu.

Xu Haibo

Thank you, Crocker. [Foreign Language].

Let me translate Mr. Xu. Thank you all. Welcome everyone, and thank you for joining us today for our first quarter of fiscal year 2009 earnings conference call. We are happy to talk that Genesis Pharmaceuticals achieved a good start to the new fiscal year. We continued the strong growth momentum of our overall base and added Radix Isatidis Dispersible Tablets to our product portfolio.

This makes us confident about our performance in the year ahead. During the course of this conference call we look forward to discussing our past operational and financial results and our outlook for the 2009 fiscal year, along with answering your questions. Thank you.

Crocker Coulson

Thank you very much, Mr. Xu and thank you [Ms. Xue]. Next, we are going to turn the call over to the company’s Chief Financial Officer Ms. Elsa Sung, and she is going to provide an update on Genesis’ Q1 operations and financial results. Elsa?

Elsa Sung

Thank you. Crocker. Once again, welcome everybody, and thank you for joining us today for our first quarter of fiscal year 2009 earnings conference call. We are pleased to share with you that Genesis Pharmaceuticals achieved strong financial results for the quarter ending September 30, 2008.

Our revenue was $27.6 million, up 65.9% from the corresponding quarter ending September 30, 2007. Gross profit was $21.8 million with a gross margin of 79.1%, up 81.3% from the corresponding quarter ending September 30, 2007.


Continues a few pages, click the link...

http://seekingalpha.com/article/106883-genesis-pharmaceuticals-enterprises-inc-f1q09-qtr-end-09-30-08-earnings-call-transcript?source=email